Median progression-free survival ( primary end point ) for axitinib ( N = 58 ) and bevacizumab ( N = 60 ) , respectively , was 5.7 and 6.1 months [ hazard ratio ( HR ) 1.09 , 95 % confidence interval ( CI ) 0.68-1 .76 ; one-sided stratified P = 0.64 ] ; median overall survival was 10.6 and 13.3 months ( HR 1.12 , 95 % CI 0.74-1 .69 ; one-sided stratified P = 0.70 ) .